These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for Kim EH; Siegel BA; Teoh EJ; Andriole GL; Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848 [TBL] [Abstract][Full Text] [Related]
4. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment. England JR; Paluch J; Ballas LK; Jadvar H Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673 [TBL] [Abstract][Full Text] [Related]
5. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment? Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105 [TBL] [Abstract][Full Text] [Related]
6. The Clinical Utility of Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884 [TBL] [Abstract][Full Text] [Related]
7. Utility of Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513 [No Abstract] [Full Text] [Related]
8. Effect of hormonal therapy on Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974 [TBL] [Abstract][Full Text] [Related]
9. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562 [TBL] [Abstract][Full Text] [Related]
10. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on Abiodun-Ojo OA; Jani AB; Akintayo AA; Akin-Akintayo OO; Odewole OA; Tade FI; Joshi SS; Master VA; Fielder B; Halkar RK; Zhang C; Goyal S; Goodman MM; Schuster DM J Nucl Med; 2021 Aug; 62(8):1089-1096. PubMed ID: 33517323 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404 [TBL] [Abstract][Full Text] [Related]
12. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281 [TBL] [Abstract][Full Text] [Related]
13. Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer. Chaussé G; Abikhzer G; Probst S Clin Nucl Med; 2018 Apr; 43(4):250-251. PubMed ID: 29465489 [TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
15. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection? Chiaravalloti A; Di Biagio D; Tavolozza M; Calabria F; Schillaci O Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373 [TBL] [Abstract][Full Text] [Related]
17. Real-world evidence of Friedrich NA; Gu L; Waller J; De Hoedt AM; Klaassen Z; Freedland SJ Prostate; 2024 Oct; 84(14):1336-1343. PubMed ID: 39031050 [TBL] [Abstract][Full Text] [Related]
18. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer. Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829 [TBL] [Abstract][Full Text] [Related]
19. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198 [No Abstract] [Full Text] [Related]